bezafibrate

基本解释

Finally, treatment of type 2 diabetic patients with bezafibrate significantly decreased OPN plasma leels.
最后，苯扎贝特治疗2型糖尿病患者可使其血浆OPN水平明显降低。
Methods:Sample was obtained from 28 patients with hypercholesterolemia(HC) and 10 healthy volunteers. Platelet aggregation (PAgT) and thromboxane B?2(TXB?2) and cAMP in platelets were studied before and after treatment with bezafibrate.
方法：分别在体内、外观察28例高胆固醇血症（HC）患者血小板聚集试验（PAgT）、凝血口恶烷B2（TXB2）及环腺苷酸（cAMP）在苯扎贝特作用前后的含量变化，并与10例健康体检者对照。
This study involved 11,177 patients with CHD who were screened for but not included in the Bezafibrate Infarction Prevention study and had no history of stroke or transient ischemic attack (TIA).
在这项研究中，共募集了经普查检出的冠状动脉心脏病病人11,177名，这些病人没有参与到苯扎贝特预防心梗的研究中，也没有脑中风或暂时性脑缺血综合症的病史。
Keywords Bezafibrate;Generation pHenyloxycarboxylic acid medicine;Synthesis;
苯扎贝特;降脂药物;合成;
Keywords headspace Gas Chromatography;residual organic solvent;bezafibrate;
顶空毛细管气相色谱法;残留溶剂;苯扎贝特;